scholarly journals Type 2 Diabetes Mellitus, Oral Antihyperglycemics, Insulin Use, and Outcomes Among Men Receiving Radiation Therapy for Prostate Cancer

2015 ◽  
Vol 93 (3) ◽  
pp. E201
Author(s):  
N.G. Zaorsky ◽  
K. Ruth ◽  
T. Shaikh ◽  
M.C. Smaldone ◽  
M.A. Hallman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Radiation Therapy ◽  
Insulin Use

Does Insulin Use Worsen the Prognosis of COVID-19 Patients with Type 2 Diabetes Mellitus? A Current Update

2021 ◽  
Vol 18 ◽  
Author(s):  
Elvan Wiyarta ◽  
Wismandari Wisnu
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Disease Progression ◽  
Grey Literature ◽  
Final Analysis ◽  
Eligibility Criteria ◽  
New Perspective ◽  
Insulin Use

Background: Insulin has recently received special attention concerning its use in COVID-19 patients. Although controversial, insulin can be able to worsen the prognosis of COVID-19 patients with Type 2 Diabetes Mellitus (T2DM) through an inflammatory pathway. This uncertain aspect brings a new perspective related to insulin use in this pandemic era. Objective: We tried to collect and analyze various studies related to this issue to provide a complete picture of the prognosis of insulin use in COVID-19 patients with T2DM. Methods: We comprehensively searched PubMed, Cochrane CENTRAL, Embase, EBSCO CINAHL, MEDLINE, and grey literature databases for studies investigating the effect of insulin on COVID-19 outcomes, including mortality, hospitalization, disease progression, other prognostic surrogates. Records were screened against the eligibility criteria. Result: 2556 articles were retrieved and were screened. A total of 8 studies were included in the final analysis. There are no studies with solid evidence supporting the effect of insulin treatment on the worsening of the prognosis of COVID-19 patients with T2DM. Although several studies have shown that insulin is associated with a poor prognosis, most studies have not considered confounders. This certainly makes it challenging to analyze the effects of insulin independently. Conclusion: We propose that COVID-19 patients with T2DM continue to receive insulin, but with careful observation of the risk of disease progression.

Prostate cancer genetic propensity risk score may modify the association between this tumour and type 2 diabetes mellitus (MCC-Spain study)

2021 ◽  
Author(s):  
Rocío Barrios-Rodríguez ◽  
Esther García-Esquinas ◽  
Beatriz Pérez-Gómez ◽  
Gemma Castaño-Vinyals ◽  
Javier Llorca ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Risk Score ◽  
Cancer Genetic

scholarly journals Men with type 2 diabetes mellitus have a lower detection rate of prostate cancer

2020 ◽  
Vol 27 (9) ◽  
pp. 817-820
Author(s):  
Mohammad‐Ali Haghsheno ◽  
Jan Hammarsten ◽  
Ralph Peeker ◽  
Carl Johan Behre ◽  
Dan Mellström ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Detection Rate ◽  
Lower Detection

Effects of sliding scale insulin use on glycemic control and length of stay in hospitalized patients with Type 2 diabetes mellitus

Therapy ◽  
2004 ◽  
Vol 1 (1) ◽  
pp. 81-85 ◽  
Author(s):  
Samy I McFarlane ◽  
Fadi El-Atat ◽  
Jonathan Castro ◽  
John Shin ◽  
Linda Joseph ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Length Of Stay ◽  
Hospitalized Patients ◽  
Sliding Scale ◽  
Insulin Use

Burden of Sliding Scale Insulin Use in Elderly Long-Term Care Residents with Type 2 Diabetes Mellitus

2013 ◽  
Vol 61 (12) ◽  
pp. 2103-2110 ◽  
Author(s):  
Naushira Pandya ◽  
Wenhui Wei ◽  
Juliana L. Meyers ◽  
Brett S. Kilpatrick ◽  
Keith L. Davis
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Long Term Care ◽  
Term Care ◽  
Sliding Scale ◽  
Insulin Use

scholarly journals Exploring the Association Between Prostate Cancer Diagnosis per se and use of GnRH Agonists and Diabetes Control in Men with type 2 Diabetes Mellitus: A Nationwide, Population-Based Cohort Study

2021 ◽  
Author(s):  
E Lin ◽  
Hans Garmo ◽  
Mieke Hemelrijck ◽  
Jan Adolfsson ◽  
Pär Stattin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cohort Study ◽  
Population Based ◽  
Diabetes Control ◽  
Gnrh Agonists ◽  
Cancer Data

Abstract Background: Gonadotropin Releasing Hormones agonists (GnRH), which are first line treatment for metastatic prostate cancer (PCa), increase risk of type 2 diabetes mellitus (T2DM). This study aims to quantify the association of use of GnRH with diabetes control in PCa men with T2DM.Methods: Nationwide population-based cohort study in the Swedish National Diabetes Register and Prostate Cancer data Base Sweden 4.1, on the association between GnRH and diabetes control in T2DM men with PCa by comparing T2DM men with PCa vs. without PCa, as well as comparing T2DM men with PCa on or not on GnRH. The primary exposure was use of GnRH. Worsening diabetes control was the primary outcome, defined as: 1) increase of HbA1c to 58 mmol/mol or higher; 2) HbA1c increase by 10 mmol/mol or more; 3) Start of antidiabetic drugs or switch to insulin; 4) combine all definitions above. Cox proportional hazards regression was used to analyze the association. Results: There were 5,714 T2DM men with PCa of whom 692 were on GnRH and 28,445 PCa-free men with T2DM with similar baseline characteristics. Diabetes control was worse in men with GnRH vs. PCa-free men (HR: 1.24, 95% CI: 1.13-1.34) as well as compared with PCa men without GnRH (HR:1.58, 95% CI: 1.39-1.80). Conclusion: Use of GnRH in T2DM men with PCa was associated with worse glycemic control. The findings highlight the need to closely monitor diabetes control in men with T2DM and PCa starting GnRH agonists and to limit the duration of their use when possible.

Sign in / Sign up

Export Citation Format

Share Document